July 29, 2026 10:37

Gerresheimer has reached an agreement with funds advised by Apax Partners to sell Centor in the United States and its global Primary Packaging Plastics business serving the pharmaceutical industry.
The deal has a combined enterprise value of approximately €1.5 billion.

The transaction covers 16 production sites in nine countries and around 2,400 employees.
In 2025, the two businesses generated combined revenue of approximately €570 million.

Gerresheimer will use the expected proceeds to reduce debt and reposition the group around higher-value drug delivery solutions, medical devices and primary packaging for injectable drugs.

The sale of Centor is expected to close by the end of the 2026 financial year, while the disposal of the Primary Packaging Plastics business is scheduled for the first half of the 2027. Both transactions remain subject to customary closing conditions and regulatory approvals.

“This transaction is an important milestone in optimizing our capital and financing structure, decreasing our leverage significantly,” said Wolf Lehmann, CFO of Gerresheimer. “We will use the expected cash inflows to accelerate our debt reduction. Together with the planned comprehensive refinancing, this will significantly reduce our interest expenses and achieve a sustainable capital structure.”

Gerresheimer offers a portfolio of primary packaging solutions, including closures and accessories, as well as drug delivery systems, medical devices and other solutions for the healthcare industry. It operates 39 production sites across Europe, the Americas and Asia and employs more than 13,000 people. Following the integration of Bormioli Pharma, acquired in December 2024, the group generated revenue of €2.321 billion in 2025.

© Polimerica -  Reproduction prohibited, all rights reserved